Disc Medicine Q1 net loss $22.8M, cash $236.4M; pipeline catalysts on track

Disc Medicine, Inc.

2023-Q1 EPS reported -$1.20

Net loss $22.8M in Q1 2023 vs $9.9M in Q1 2022; R&D expenses $20.2M including $10M Mabwell upfront.
Cash and equivalents $236.4M at March 31, 2023, up from $194.6M; funding expected into 2025.
Bitopertin Phase 2 BEACON interim data at EHA June 9, 2023; topline from BEACON and AURORA by end 2023.
DISC-0974 Phase 1b/2 in NDD-CKD and MF anemia; interim data expected by end of 2023.
In-licensed anti-TMPRSS6 mAbs from Mabwell; Phase 1 trial planned for second half 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Disc Medicine, Inc. reported financial results for first quarter ending March 31, 2023.

Period: first quarter ending March 31, 2023
Result: reported results

Exact text from the filing

Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-144146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.